AmMax Partnering
AmMax is built on the partnership with Amgen via the licensing of a potent monoclonal antibody targeting CSF1R. We plan to continue to build out the CSF1R technology platform through research collaborations.

AmMax is built on the partnership with Amgen via the licensing of a potent monoclonal antibody targeting CSF1R. We plan to continue to build out the CSF1R technology platform through research collaborations.